Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 41, Issue 4, 2016, Pages 363-372

  Chen, Rong ^a   Qian, Qing ^a   Sun, Meng ru ^a   Qian, Chun yan ^a   Zou, Su lan ^a   Wang, Ming li ^a   Wang, Li ying ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PIPERACILLIN; TAZOBACTAM; ANTIINFECTIVE AGENT; PENICILLANIC ACID; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

ACINETOBACTER BAUMANNII; ADULT; ARTICLE; BACTERIUM ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; ESCHERICHIA COLI; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; MALE; MATHEMATICAL MODEL; MATHEMATICAL PARAMETERS; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MODEL; MONTE CARLO METHOD; NONLINEAR MIXED EFFECTS MODEL; OBJECTIVE FUNCTION VALUE; POPULATION PHARMACOKINETIC PHARMACODYNAMICS MODEL; PREDICTIVE VALUE; PROBABILITY OF TARGET ATTAINMENT; PSEUDOMONAS AERUGINOSA; SIMULATION; STEADY STATE; TIME SERIES ANALYSIS; UREA NITROGEN BLOOD LEVEL; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; BODY WEIGHT; CROSS INFECTION; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; MICROBIAL SENSITIVITY TEST; PROCEDURES;

ANTI-BACTERIAL AGENTS; BODY WEIGHT; CROSS INFECTION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PENICILLANIC ACID; PIPERACILLIN;

EID: 84928136651     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-015-0276-3     Document Type: Article

References (20)

1. Wang H, Zhang B, Ni Y, Kuti JL, Chen B, Chen M, Nicolau DP. Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004. Int J Antimicrob Agents. 2007;30(452):457.
2. Sadaba B, Azanza JR, Campanero MA, Garcia-Quetglas E. Relationship between pharmacokinetics and pharmacodynamics of beta-lactams and outcome. Clin Microbiol Infect. 2004;10(990):998.
3. Vinks AA, Den Hollander JG, Overbeek SE, Jelliffe RW, Mouton JW. Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis. Antimicrob Agents Chemother. 2003;47(541):547.
4. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(31):41.
5. Shea KM, Cheatham SC, Wack MF, Smith DW, Sowinski KM, Kays MB. Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients. Int J Antimicrob Agents. 2009;34(429):433.
6. Di Giovamberardino G, Ferrannini M, Testore GP, Federici G, Pastore A. High performance liquid chromatographic determination of plasma free and total tazobactam and piperacillin. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877(86):88.
7. Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn. 2001;28(231):252.
8. Arzuaga A, Maynar J, Gascon AR, Isla A, Corral E, Fonseca F, Sanchez-Izquierdo JA, Rello J, Canut A, Pedraz JL. Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration. J Clin Pharmacol. 2005;45(168):176.
9. Asin-Prieto E, Rodriguez-Gascon A, Troconiz IF, Soraluce A, Maynar J, Sanchez-Izquierdo JA, Isla A. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis. J Antimicrob Chemother. 2014;69(180):189.
10. Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother. 2005;56(388):395.
11. Li Z, Chen Y, Li Q, Cao D, Shi W, Cao Y, Wu D, Zhu Y, Wang Y, Chen C. Population pharmacokinetics of piperacillin/tazobactam in neonates and young infants. Eur J Clin Pharmacol. 2013;69(1223):1233.
12. Parke J, Holford NH, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed. 1999;59(19):29.
13. Sorgel F, Kinzig M. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J Antimicrob Chemother. 1993;31(Suppl A):39–60.
14. Bauer SR, Salem C, Connor MJ Jr, Groszek J, Taylor ME, Wei P, Tolwani AJ, Fissell WH. Pharmacokinetics and pharmacodynamics of piperacillin–tazobactam in 42 patients treated with concomitant CRRT. Clin J Am Soc Nephrol. 2012;7(452):457.
15. Cheatham SC, Fleming MR, Healy DP, Chung CE, Shea KM, Humphrey ML, Kays MB. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients. Int J Antimicrob Agents. 2013;41(52):56.
16. Butterfield JM, Lodise TP, Beegle S, Rosen J, Farkas J, Pai MP. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations. J Antimicrob Chemother. 2014;69(176):179.
17. Kim MK, Xuan D, Quintiliani R, Nightingale CH, Nicolau DP. Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin–tazobactam. J Antimicrob Chemother. 2001;48(259):267.
18. Masterton RG, Kuti JL, Turner PJ, Nicolau DP. The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe. J Antimicrob Chemother. 2005;55(71):77.
19. Ambrose PG, Bhavnani SM, Jones RN. Pharmacokinetics–pharmacodynamics of cefepime and piperacillin–tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program. Antimicrob Agents Chemother. 2003;47(1643):1646.
20. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007;44(357):363.